In related news, other scientists recently reported that phospho-tau isoforms in the CSF mirror protofibrillar forms of tau, ...

(RTTNews) - Biogen Inc. (BIIB), a biotechnology company and Eisai Co., Ltd. On Friday provided an update on the regulatory review of lecanemab as a treatment for early Alzheimer's disease or AD in ...

Viehbacher, "Biogen") announced today an update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab as treatment for early AD (mild cognitive impairment due ...

These questions will now be discussed at the CHMP meeting in February 2025, before the Commission can take a final decision on the Marketing Authorization Application for lecanemab as treatment ...

Viehbacher, “Biogen”) announced today an update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab as ... of amyloid-beta (Aβ). Since July 2020 the ...

Kelley agreed, noting that many patients at UT Southwestern are choosing donanemab over lecanemab now. Some clinicians said they would want to evaluate plaque level via PET scan before deciding ...

Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble ...

2021; Yamazaki et al., 2019). In late-onset AD, which occurs sporadically after the age of 65, the impairment of amyloid β-protein (Aβ) clearance mechanisms seems to be a primary factor in the ...

CNET’s expert staff reviews and rates dozens of new products and services each month, building on more than a quarter century of expertise.